# Enveric Biosciences, Inc.: financial statements, quarterly

ENVB · Nasdaq · CIK 890821 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/envb.md) · [Financials](/companies/envb/financials.md) · [Filings](/companies/envb/filings.md) · [Insiders](/companies/envb/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/envb/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $k | [1,281](/filings/0001493152-24-045859.md) | [1,721 d](/filings/0001641172-25-001296.md) | [506](/filings/0001641172-25-010345.md) | [565](/filings/0001641172-25-024021.md) | [803](/filings/0001493152-25-023540.md) | [967 d](/filings/0001493152-26-013294.md) | [746](/filings/0001493152-26-023353.md) | [1,260](/filings/0001493152-26-038418.md) | [402](/filings/0001493152-25-023540.md) | [372 d](/filings/0001493152-26-013294.md) | [346](/filings/0001493152-26-023353.md) | [1,355](/filings/0001493152-26-038418.md) |
| Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(3,448)](/filings/0001493152-24-045859.md) | [(2,384) d](/filings/0001641172-25-001296.md) | [(2,477)](/filings/0001641172-25-010345.md) | [(1,898)](/filings/0001641172-25-024021.md) | [(2,083)](/filings/0001493152-25-023540.md) | [(3,174) d](/filings/0001493152-26-013294.md) | [(2,188)](/filings/0001493152-26-023353.md) | [(2,519)](/filings/0001493152-26-038418.md) | [(1,874)](/filings/0001493152-25-023540.md) | [(2,194) d](/filings/0001493152-26-013294.md) | [(1,633)](/filings/0001493152-26-023353.md) | [(3,027)](/filings/0001493152-26-038418.md) |
| Interest expense | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $k | [6.6](/filings/0001493152-24-045859.md) | [22.3 d](/filings/0001641172-25-001296.md) | [1.7](/filings/0001641172-25-010345.md) | [0.0 d](/filings/0001641172-25-024021.md) | [0.0 d](/filings/0001493152-25-023540.md) | [7.2 d](/filings/0001493152-26-013294.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,822)](/filings/0001493152-24-045859.md) | [(3,436) d](/filings/0001641172-25-001296.md) | [(2,457)](/filings/0001493152-25-023540.md) | [(1,879)](/filings/0001493152-25-023540.md) | [(2,084)](/filings/0001493152-25-023540.md) | [(3,155) d](/filings/0001493152-26-013294.md) | [(2,185)](/filings/0001493152-26-038418.md) | [(2,519)](/filings/0001493152-26-038418.md) | [(1,874)](/filings/0001493152-25-023540.md) | [(2,194) d](/filings/0001493152-26-013294.md) | [(1,633)](/filings/0001493152-26-038418.md) | [(3,028)](/filings/0001493152-26-038418.md) |
| Diluted EPS | $ per share | [(1.30)](/filings/0001493152-24-045859.md) | not reported | [(9.21)](/filings/0001641172-25-010345.md) | [(3.72)](/filings/0001641172-25-024021.md) | [(43.10)](/filings/0001493152-25-023540.md) | not reported | [(14.58)](/filings/0001493152-26-023353.md) | [(11.65)](/filings/0001493152-26-038418.md) | [(10.81)](/filings/0001493152-25-023540.md) | not reported | [(1.08)](/filings/0001493152-26-023353.md) | [(0.76)](/filings/0001493152-26-038418.md) |
| Basic EPS | $ per share | [(1.30)](/filings/0001493152-24-045859.md) | not reported | [(9.21)](/filings/0001641172-25-010345.md) | [(3.72)](/filings/0001641172-25-024021.md) | [(43.10)](/filings/0001493152-25-023540.md) | not reported | [(14.58)](/filings/0001493152-26-023353.md) | [(11.65)](/filings/0001493152-26-038418.md) | [(10.81)](/filings/0001493152-25-023540.md) | not reported | [(1.08)](/filings/0001493152-26-023353.md) | [(0.76)](/filings/0001493152-26-038418.md) |

- Revenue: not reported
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $k | [4,267](/filings/0001493152-23-040493.md) | [2,288](/filings/0001641172-25-001296.md) | [6,356](/filings/0001493152-24-019364.md) | [3,503](/filings/0001493152-24-031352.md) | [3,112](/filings/0001493152-24-045859.md) | [2,241](/filings/0001493152-26-013294.md) | [4,294](/filings/0001641172-25-010345.md) | [2,850](/filings/0001641172-25-024021.md) | [3,758](/filings/0001493152-25-023540.md) | [4,677](/filings/0001493152-26-038418.md) | [4,909](/filings/0001493152-26-038418.md) | [8,296](/filings/0001493152-26-038418.md) |
| Current assets | $k | [5,827](/filings/0001493152-23-040493.md) | [3,582](/filings/0001641172-25-001296.md) | [8,229](/filings/0001493152-24-019364.md) | [5,520](/filings/0001493152-24-031352.md) | [4,338](/filings/0001493152-24-045859.md) | [2,735](/filings/0001493152-26-013294.md) | [4,835](/filings/0001641172-25-010345.md) | [3,307](/filings/0001641172-25-024021.md) | [4,166](/filings/0001493152-25-023540.md) | [4,937](/filings/0001493152-26-038418.md) | [5,375](/filings/0001493152-26-023353.md) | [8,793](/filings/0001493152-26-038418.md) |
| Total assets | $k | [6,619](/filings/0001493152-23-040493.md) | [4,300](/filings/0001641172-25-001296.md) | [8,850](/filings/0001493152-24-019364.md) | [6,052](/filings/0001493152-24-031352.md) | [4,790](/filings/0001493152-24-045859.md) | [3,083](/filings/0001493152-26-013294.md) | [5,102](/filings/0001641172-25-010345.md) | [3,548](/filings/0001641172-25-024021.md) | [4,362](/filings/0001493152-25-023540.md) | [5,096](/filings/0001493152-26-038418.md) | [5,521](/filings/0001493152-26-023353.md) | [8,944](/filings/0001493152-26-038418.md) |
| Current liabilities | $k | [4,184](/filings/0001493152-23-040493.md) | [2,344](/filings/0001641172-25-001296.md) | [2,368](/filings/0001493152-24-019364.md) | [645](/filings/0001493152-24-031352.md) | [839](/filings/0001493152-24-045859.md) | [1,490](/filings/0001493152-26-013294.md) | [1,184](/filings/0001641172-25-010345.md) | [1,364](/filings/0001641172-25-024021.md) | [906](/filings/0001493152-25-023540.md) | [918](/filings/0001493152-26-038418.md) | [461](/filings/0001493152-26-023353.md) | [861](/filings/0001493152-26-038418.md) |
| Total liabilities | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $k | [2,436](/filings/0001493152-24-045859.md) | [1,956](/filings/0001493152-26-013294.md) | [6,482](/filings/0001493152-25-023540.md) | [5,406](/filings/0001493152-25-023540.md) | [3,951](/filings/0001493152-25-023540.md) | [1,593](/filings/0001493152-26-038418.md) | [3,918](/filings/0001493152-26-038418.md) | [2,185](/filings/0001493152-26-038418.md) | [3,456](/filings/0001493152-25-023540.md) | [4,178](/filings/0001493152-26-038418.md) | [5,061](/filings/0001493152-26-038418.md) | [8,083](/filings/0001493152-26-038418.md) |

- Cash and equivalents: us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: not reported
- Current portion of debt: not reported
- Short-term borrowings: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(2,740) d](/filings/0001493152-24-045859.md) | [(1,751) d](/filings/0001641172-25-001296.md) | [(2,598)](/filings/0001641172-25-010345.md) | [(2,889) d](/filings/0001641172-25-024021.md) | [(927) d](/filings/0001493152-25-023540.md) | [(1,312) d](/filings/0001493152-26-013294.md) | [(2,392)](/filings/0001493152-26-023353.md) | [(1,890) d](/filings/0001493152-26-038418.md) | [(2,075) d](/filings/0001493152-25-023540.md) | [(1,785) d](/filings/0001493152-26-013294.md) | [(2,257)](/filings/0001493152-26-023353.md) | [(2,445) d](/filings/0001493152-26-038418.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001493152-24-045859.md) | [(0.0) d](/filings/0001641172-25-001296.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [1,787](/filings/0001493152-23-040493.md) | [2,078](/filings/0001493152-24-019364.md) | [2,108](/filings/0001493152-24-031352.md) | [2,165](/filings/0001493152-24-045859.md) | [267](/filings/0001641172-25-010345.md) | [506](/filings/0001641172-25-024021.md) | [48.4](/filings/0001493152-25-023540.md) | [150](/filings/0001493152-26-023353.md) | [216](/filings/0001493152-26-038418.md) | [313](/filings/0001493152-25-023540.md) | [1,510](/filings/0001493152-26-023353.md) | [3,987](/filings/0001493152-26-038418.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,475,884 at 2026-08-12, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038418.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:27 ET. No prices; not investment advice.